Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Aurobindo Pharma Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Aurobindo Pharma Ltd (AUROPHARMA-IN)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

01 Nov 2016 Thomson Reuters Stock Report 11 $25.00

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceut...

17 Oct 2016 GlobalData 74 $300.00

Company Snapshot - Aurobindo Pharma Limited

A director at Aurobindo Pharma Limited sold 2,165,128 shares at 0.000INR and the significance rating of the trade was 100/100...

10 Oct 2016 Directors Deals Ltd. 1 $12.00

Aurobindo Pharma (ARBP) - Company Update - Dated - October 05, 2016

Aurobindo Pharma (Bloomberg: ARBP IN, BUY, TP: Rs 970; 12% upside from CMP of Rs 865) We met Mr. Robert Cunard (CEO, Aurob...

06 Oct 2016 Axis Capital Limited 7 $69.00

Wright Investors Service Comprehensive Report for Aurobindo Pharma Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

23 Sep 2016 Wright Reports 64 $75.00

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review

Aurobindo Pharma Ltd (AUROPHARMA) - Financial Analysis Review Summary Aurobindo Pharma Ltd (Aurobindo Pharma) is a pharmaceut...

16 Sep 2016 GlobalData 66 $300.00

MOSL: AUROBINDO PHARMA 1QFY17 (Buy)-Margin improvement continues; US growth to excel further

AUROBINDO PHARMA 1QFY17: Margin improvement continues; US growth to excel further (ARBP IN, Mkt Cap USD6.9b, CMP INR788, TP ...

25 Aug 2016 Motilal Oswal Securities Ltd. 12 $115.00

Spark Capital: 1QFY17 Outlook Review of Aurobindo Pharma (Rating: BUY, TP: Rs. 900)

1QFY17 Outlook Review of Aurobindo Pharma (Rating: BUY, TP: Rs. 900) How does our one year outlook change? We m...

25 Aug 2016 Spark Capital Advisors(India) Private Limited 6 $46.00

Aurobindo Pharma | Q1FY17 Result Update | Strong management commendatory. High growth should be visible from H2FY17 onwards. Maintain Buy with target of Rs 1012.

Aurobindo Pharma | Q1FY17 Result Update Strong management commendatory. High growth should be visible from H2FY17 onwards. M...

24 Aug 2016 IndiaNivesh Securities Pvt Ltd 7 $69.00